Comparison of Explicit, Implicit and no Values Clarification Decision Aids for Men Considering Prostate Cancer Screening

Condition:   Healthy Volunteers Interventions:   Other: Decision aid with implicit values clarification method (booklet or website);   Other: Decision aid with explicit values clarification method (booklet or website) Sponsors:   Universidade do Porto;   NOVA Medical School;   Georgetown University Not yet recruiting
Source: - Category: Research Source Type: clinical trials

Related Links:

Patient decision aids (PDAs) can support the treatment decision making process and empower patients to take a proactive role in their treatment pathway while using a shared decision-making (SDM) approach makin...
Source: BMC Medical Informatics and Decision Making - Category: Information Technology Authors: Tags: Technical advance Source Type: research
This study describes the development and i...
Source: BMC Medical Research Methodology - Category: Research Authors: Tags: Research article Source Type: research
To evaluate barriers to implementation of patient decision aids (PDAs) issued in an electronic medical record (EMR). We undertook an implementation outcomes analysis focused on what proportion of men eligible for the PDA received it (penetration), and of the men who received it, how many used it as intended (fidelity). We also evaluated various patient centered outcomes related to decision making.
Source: Urology - Category: Urology & Nephrology Authors: Source Type: research
AbstractUptake of decision aids (DAs) in daily routine is low, resulting in limited knowledge about successful DA implementation at a large scale. We assessed implementation rates after multi-regional implementation of three different prostate cancer (PCa) treatment DAs and patient-perceived barriers and facilitators to use a DA. Thirty-three hospitals implemented one out of the three DAs in routine care. Implementation rates for each DA were calculated per hospital. After deciding about PCa treatment, patients (n = 1033) completed a survey on pre-formulated barriers and facilitators to use a DA. Overall DA i...
Source: Journal of Cancer Education - Category: Cancer & Oncology Source Type: research
Interview with Kari A O Tikkinen, MD, PhD, author of Decision Aids for Prostate Cancer Screening Choice: A Systematic Review and Meta-analysis
Source: JAMA Specialty Journals Author Interviews - Category: General Medicine Source Type: podcasts
This systematic review and meta-analysis of 19 randomized clinical trials estimates the association of decision aids with decisional outcomes in prostate cancer screening.
Source: JAMA Internal Medicine - Category: Internal Medicine Source Type: research
In 2009, routine prostate cancer screening using a prostate-specific antigen (PSA) test was described as “the controversy that refuses to die.”(p1351) Unfortunately, 10 years later, the controversy is still alive and thriving. Clinical trials have failed to resolve whether or to what degree screening using PSA tests help reduce prostate cancer –specific mortality, and it has long been clear that PSA screening tests increase the diagnosis of low-risk cancers and can lead to patient harm from potentially unnecessary biopsies and cancer treatment. As a result, many expert groups recommend shared decision-mak...
Source: JAMA Internal Medicine - Category: Internal Medicine Source Type: research
PET imaging with radiotracers to accurately identify molecules in cancer cells...Read more on AuntMinnie.comRelated Reading: PET tracer may aid diagnosis of inflammatory bowel disease Immuno-PET tracer offers hope for early cancer treatment Novel PET tracer could identify bacterial infections Immuno-PET radiotracers may aid cancer treatment Novel PET tracer aids recurrent prostate cancer patients
Source: Headlines - Category: Radiology Source Type: news
Go online to to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this PeerView MasterClass, an expert panel of oncology nurse professionals presents the highlights of emerging science and clinical data on PARP inhibition in multiple solid tumors, assesses the role of companion diagnostic tests that identify patients with DDR mutations, as well as engage the audience in a stimulating discussion on the value of genetic testing and significance of enrollment in ongoing PARP inhibitor clinical trials. Going beyond the standard didactic lectures, our experts...
Source: PeerView CME/CE Audio Podcast - Oncology - Category: Cancer & Oncology Authors: Tags: Science, Medicine Source Type: podcasts
More News: Cancer | Cancer & Oncology | HIV AIDS | Prostate Cancer | Research | Websites